- Gilead and Merck’s latest trial success and flopAstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition, and more biotech news from The ReadoutSTAT · 1mo ago↗ source
- STAT+: NIAID appoints new acting director after weekslong questions over leadershipThe NIH has appointed researcher John Powers III to lead its infectious disease institute on an acting basis, after weeks of being in leadership limbo.STAT · 1mo ago↗ source
- STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and moreGSK agreed to buy Nuvalent, a cancer drug developer, in a deal worth $10.6 billion, as the company continues its expansion in oncologySTAT · 1mo ago↗ source